Plattenepithelkarzinom des Kopf-Hals-Bereichs: Palliative Systemtherapie

Plattenepithelkarzinome des Kopf-Hals-Bereichs gehören zu den häufigsten Krebserkrankungen und haben im fortgeschrittenen Stadium eine schlechte Prognose. In diesem Beitrag zeigen wir die aktuellen Entwicklungen im Bereich der palliativen Systemtherapie auf. Wir fokussieren uns auf den Stellenwert der Immuntherapie mit Checkpoint-Inhibitoren, der klassischen zytostatischen Therapie und neuer Therapiekonzepte – mit einem Schwerpunkt auf die praktische Anwendung.

Schlüsselwörter

Oropharynxkarzinom - Hypopharynxkarzinom - Larynxkarzinom - Metastasen - Immuntherapie - zielgerichtete Therapie - Zytostatika - monoklonale Antikörper

• Literatur

• 1 Vermorken JB. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 (11) 1116-1127
• 2 Mandal R. et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016; 1 (17) e89829
• 3 Burtness B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet 2019; 394: 1915-1928
• 4 Ferris RL. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375 (19) 1856-1867
• 5 Dietz A. et al. HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany. Journal of Clinical Oncology 2020; 38 (Suppl. 15) 6532-6532
• 6 Guigay J. et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology 2021; 22 (04) 463-475
• 7 Wormann B. et al. Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. Oncol Res Treat 2020; 43 (11) 628-636
• 8 Knoedler M. et al. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology 2013; 84 (05) 284-289
• 9 Plazy C, Hannani D, Gobbini E. Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review. Curr Oncol Rep 2022;
• 10 Cohen EEW. et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 2019; 7 (01) 184
• 11 Kimura T. et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1–6 hepatocellular carcinoma model. Cancer Sci 2018; 109 (12) 3993-4002
• 12 Alsahafi E. et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 2019; 10 (08) 540